tbuckley/cabot-search huggingface dataset:
Eliminating waste in healthcare spending
Authors: Kalipso Chalkidou, John Appleby
Journal: BMJ (2017)

Eliminating waste in healthcare spendingThere is no silver bullet-just incremental change based on good data Kalipso Chalkidou and John ApplebyHealth systems in all countries-no matter how they are organised, funded, and regulated-should strive to maximise benefits to patients for every pound, dollar, or euro they spend.The cost of not doing so can be measured in money terms-but, more importantly, in death, pain, and disability that could have been averted.But, as the Organisation for Economic Cooperation and Development (OECD) pointed out recently, a considerable chunk of the world's health spending is probably wasted, and the key determinants of the level of wasteful spending are the organisation, funding, and regulation of countries' healthcare systems.
The Hydroxyurea Effects on Plasma Levels and Surface Expression of Adhesion Molecules ICAM-1 VCAM-1, E-SELECTIN and on Plasma Levels of Protein C and Protein S in Patients with Sickle Cell Disease and β-Thalassemia Intermedia
Authors: Gaetano Giuffrida, maria Rocca Cingari, Nunziatina Laura Parrinello, Amalia Figuera
Journal: Blood (2008)
A Phase 1 Trial of Fluphenazine HCl (Fz), a Serotonin Antagonist, in Relapsed and Refractory Multiple Myeloma
Authors: Edward A. Stadtmauer, David Siegel, Dan T Vogl, James Stinnett, Geetha Narayanan, P.P. Bapsy, Trivadi Ganesan, Minish Jain, Sripada V.S.S Prasad, Douglas S McNair, Linda DeYoung, Alice Lane, Bruce Silver
Journal: Blood (2008)
Serum Fructosamine As an Alternative to Glycated Hemoglobin (HbA1c) for Glycemic Assessment in Diabetic Patients with Hemoglobin (Hb) Louisville
Authors: Mercedes Lorenzo-Medina, Silvia De-La-Iglesia, Lucia Quintana-Hidalgo, Lidia Ruiz-Garcia, Ruth Martin-Alfaro, Juan Herrada
Journal: Blood (2012)
A Novel Multiparameter Flow Cytometric Cytotoxicity Assay Detects p53 Deletion as the Major Cause of In Vitro Resistance to Fludarabine in B-Cell Chronic Lymphocytic Leukemia.
Authors: James Z. Huang, Antony C. Bakke, Guang Fan, Rita Braziel, Ken M. Gatter, Richard T. Maziarz, Jose F. Leis, Yanping Zhong
Journal: Blood (2005)
Bmab+oral 5-FU therapy is appropriate for first-line treatment of elderly patients with ARCC
Authors: Kazuma Kobayashi, Kantoku Nagakawa, Fumihiko Fujita, Yusuke Inoue, Satomi Okada, Shunsuke Murakami, Kengo Kanetaka, Kosho Yamanouchi, Tamotsu Kuroki, Susumu Eguchi
Journal: Annals of Oncology (2016)
Analgesic use and the risk of renal cell carcinoma (RCC): Results from a large up-to-date meta-analysis.
Authors: Eunyoung Cho, Youjin Je, Toni K. Choueiri
Journal: Journal of Clinical Oncology (2012)

395 Background: Analgesics have been linked to an increased risk of developing renal cell carcinoma (RCC), but the evidence is mixed. Using a meta-analysis design of all available studies, we investigated the association between analgesic use and RCC risk. Methods: We searched the MEDLINE database to identify eligible case-control or cohort studies published in English from 1966 to July 1, 2011 for 3 categories of analgesics: acetaminophen, aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). Study-specific effect estimates were pooled to compute an overall relative risk (RR) and its 95% confidence interval (CI), using a random effects model, for each category of the analgesics. Analyses were conducted according to regular/any use and high dose or long-duration of use, separately. Results: We identified 18 studies (12 for acetaminophen, 12 for aspirin, and 5 for other NSAIDs) that were performed in 6 countries. Regular/any use of acetaminophen and other NSAIDs were each associated with an increased risk of RCC: pooled RR, 1.33 (95% CI 1.18-1.49) for acetaminophen and 1.26 (95% CI, 1.09-1.44) for other NSAIDs, respectively. For use of aspirin, we found no significant increased risk (pooled RR, 1.14 [95% CI, 0.98-1.33]). Similar risk trends were seen with high dose of analgesics intake. No significant difference in associations was found by study design (case-control vs. cohort), type of controls in case-control study (population based vs. hospital based), outcome (RCC vs. kidney cancer), and gender (male vs. female). There was no indication of publication bias for the 3 analgesics. Conclusions: In this meta-analysis of analgesics use and RCC risk, we found that use of acetaminophen and non-aspirin NSAIDs was associated with a significant increased risk of developing RCC.
Results from a Phase 1/2, Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma
Authors: Madeleine Duvic, Steven M Horwitz, Youn H Kim, Pier Luigi Zinzani, Gajanan Bhat, Pankaj Sharma, Sue Yancik
Journal: Blood (2015)
Analysis of left ventricular performance after mitral valve replacement with a technique of preservation of all chordae tendineae : Comparison with conventional mitral valve replacement or mitral valve repair : Chairperpons remarks
Authors: Yutaka Okita, Shigehito Miki, Kenji KusHhara, Yuichi Ueda, Takafumi Tahata, Tetsuro Sakai, Katsuhiko Matsuyama
Journal: Circulation (1993)
A Novel Protease, PRSS33 (serine protease 33), Is Specifically and Constitutively Expressed in Eosinophils
Authors: Sumika Toyama, Okada Naoko, Akio Matsuda, Hirohisa Saito, Susumu Nakae, Hajime Karasuyama, Kenji Matsumoto
Journal: Journal of Allergy and Clinical Immunology (2017)
Annals Story Slam - Goodbyes
Authors: Mitchell J. Cohen
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 February 2017Annals On Being a Doctor Story Slam - GoodbyesFREEMitchell J. Cohen, MDMitchell J. Cohen, MDFrom Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0018 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Goodbyes "Goodbyes," by Mitchell Cohen, MD (Duration 6:10)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Current Author Address: Mitchell J. Cohen, MD, Thomas Jefferson University Hospital, Philadelphia, PA; e-mail, Mitchell.[email protected]edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 February 2017Volume 166, Issue 3Page: SS1 ePublished: 7 February 2017 Issue Published: 7 February 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Phase I study of anti-VEGF receptor-3 (VEGFR-3) monoclonal antibody (mab) LY3022856/IMC-3C5 (3C5).
Authors: Wasif M. Saif, James A. Knost, E. Gabriela Chiorean, Siva Rama Prasad Kambhampati, Danni Yu, Bronislaw Pytowski, Amy Qin, John S. Kauh, Bert H. O'Neil
Journal: Journal of Clinical Oncology (2015)

3530 Background: Many cancers metastasize to regional lymph nodes (LN). LN involvement by tumor is an adverse prognostic factor. 3C5 is a human IgG1 mab to VEGFR-3, which is a principal mediator of lymphangiogenesis (LA). Methods: This was a first-in-human study (NCT01288989). Part A (A) was a dose escalation study, followed by Part B (B), a planned 15-patient (pt) colorectal (CRC) expansion cohort. The primary endpoint of A was to establish the safety profile and maximum tolerated dose of 3C5 in pts with advanced solid tumors refractory to standard therapy: for B was to establish safety, tolerability, and dose confirmation in pts with advanced refractory CRC. Secondary objectives were pharmacokinetics (PK; noncompartmental parameters), antitumor activity, and immunogenicity. Pharmacodynamics was an exploratory objective. Results: Between April 2011 and August 2014, 44 pts were treated (23 in A, 21 in B): median age 58 years (range 33 to 79), male 59%, white 82%, black 9%, Asian 9%; median weight 77 kg (range 52 to 132). Starting dose was 5 mg/kg weekly (qwk), escalated to 10 mg/kg qwk and 20 mg/kg qwk and reached the highest planned dose of 30 mg/kg qwk without dose limiting toxicity. Treatment-emergent adverse events (AE) of any grade occurring in more than 15% of patients were: nausea 41%, fatigue 32%, vomiting 30%, anorexia 27%, pyrexia 25%, edema 23%, urinary tract infection (UTI) 21%, constipation 18%, cough 18%, and hypoalbuminemia 16%, diarrhea 16%. The most common grade 3/4 AEs were UTI, small bowel obstruction 7% each, and nausea, dyspnea, anemia, hypomagnesemia, pneumonia, bile duct stenosis 5% each. No responses per RECIST were noted. 4 of 8 pts with CRC treated at 30 mg/kg on A had prolonged progression free survival (PFS) (10 to 39 weeks). In B, 3C5 at 30 mg/kg qwk resulted in a median PFS of 6.3 weeks (95% confidence interval = 5.1, 14.4). No significant changes in serum VEGF-C/D levels were detected from pt samples after 3C5 administration. Conclusions: 3C5 was well tolerated up to a dose of 30 mg/kg qwk. 3C5 does not appear to have significant anti-tumor activity as monotherapy in CRC. Future development will be considered in indications in which LA plays a prominent role. Clinical trial information: NCT01288989.
Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity
Authors: Barbara Oliviero, Stefania Mantovani, Stefania Varchetta, Dalila Mele, Giulia Grossi, Serena Ludovisi, Elisa Nuti, Armando Rossello, Mario U. Mondelli
Journal: Journal of Hepatology (2017)
Decreased Incidence of GvHD after Reduced Intensity Conditioning and a Fixed T-CELL Dose in Hematological Malingnancy Patients
Authors: Audrey Simon, Eddy Roosnek, Yordanka Tirefort, Yan Beauverd, Carole Dantin, Olga Tsopra, Jakob R. Passweg, Stavroula Masouridi-Levrat, Yves Chalandon
Journal: Blood (2014)
The 3′ End of the Chicken Hypersensitive Site-4 Insulator Has Properties Similar to the 5′ Insulator Core and Is Necessary in Conjunction with the Core for Full Insulator Activity
Authors: Paritha Arumugam, Fabrizia Urbinati, Chinavenmeni S. Velu, H. Leighton Grimes, Punam Malik
Journal: Blood (2008)
Extracellular RNAs Are Associated With Insulin Resistance and Metabolic Phenotypes
Authors: Ravi Shah, Venkatesh Murthy, Michael Pacold, Kirsty Danielson, Kahraman Tanriverdi, Martin G. Larson, Kristina Hanspers, Alexander Pico, Eric Mick, Jared Reis, Sarah de Ferranti, Elizaveta Freinkman, Daniel Levy, Udo Hoffmann, Stavroula Osganian, Saumya Das, Jane E. Freedman
Journal: Diabetes Care (2017)

Insulin resistance (IR) is a hallmark of obesity and metabolic disease. Circulating extracellular RNAs (ex-RNAs), stable RNA molecules in plasma, may play a role in IR, though most studies on ex-RNAs in IR are small. We sought to characterize the relationship between ex-RNAs and metabolic phenotypes in a large community-based human cohort.We measured circulating plasma ex-RNAs in 2,317 participants without diabetes in the Framingham Heart Study (FHS) Offspring Cohort at cycle 8 and defined associations between ex-RNAs and IR (measured by circulating insulin level). We measured association between candidate ex-RNAs and markers of adiposity. Sensitivity analyses included individuals with diabetes. In a separate cohort of 90 overweight/obese youth, we measured selected ex-RNAs and metabolites. Biology of candidate microRNAs was investigated in silico.The mean age of FHS participants was 65.8 years (56% female), with average BMI 27.7 kg/m2; participants in the youth cohort had a mean age of 15.5 years (60% female), with mean BMI 33.8 kg/m2. In age-, sex-, and BMI-adjusted models across 391 ex-RNAs in FHS, 18 ex-RNAs were associated with IR (of which 16 were microRNAs). miR-122 was associated with IR and regional adiposity in adults and IR in children (independent of metabolites). Pathway analysis revealed metabolic regulatory roles for miR-122, including regulation of IR pathways (AMPK, target of rapamycin signaling, and mitogen-activated protein kinase).These results provide translational evidence in support of an important role of ex-RNAs as novel circulating factors implicated in IR.
Evaluation of Peanut and Other Fruit Tolerance after Slit with Ltp (Pru p 3) in Allergic Patients Sensitized By Ara h 9
Authors: Francisca Gomez, Bogas Gador, Esther Barrionuevo, Raquel Jurado, Miguel Gonzalez, A.N.A. Prieto, Maria Jose Rodriguez, Maria J. Torres, Cristobalina Mayorga
Journal: Journal of Allergy and Clinical Immunology (2017)
Effectiveness of Medication Adherence Reminders Tied to “Fresh Start” Dates
Authors: Hengchen Dai, David Mao, Jason Riis, Kevin G. Volpp, Michael J. Relish, Victor F. Lawnicki, Katherine L. Milkman
Journal: JAMA Cardiology (2017)

This randomized clinical trial examines whether sending medication adherence reminders around fresh-start dates, such as birthdays or New Year's Day, and highlighting these dates as an opportunity for positive changes could boost reminders' effectiveness.
Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC
Authors: F. Barlesi, K. Park, F. Ciardiello, J. von Pawel, S. Gadgeel, T. Hida, D. Kowalski, M.C. Dols, D. Cortinovis, J. Leach, J. Polikoff, D. Gandara, C.H. Barrios, D.S. Chen, P. He, M. Kowanetz, M. Ballinger, D. Waterkamp, A. Sandler, A. Rittmeyer
Journal: Annals of Oncology (2016)
RBIO-05. miRNAs THAT CONFER GLIOBLASTOMA RESISTANCE: IS THE COMBINATION MERELY A SUM OF THE PARTS?
Authors: Clark Chen, Patryk Moskwal, Pascal Zinn, Young Eun Choi, Sachet Shukla, Wojciech Fendler, Jun Lu, Todd Golub, Anita Hjelmeland, Dipanjan Chowdhury
Journal: Neuro-Oncology (2016)

Most studies of miRNA focus on the biology of single miRNA. How miRNAs interact with one another to modulate complex biologic effects, such as radiation resistance, remain poorly understood. An unbiased functional microRNA screen identified four miRNAs (miR1, miR125a, miR150, and miR425) that, when expressed together, induced glioblastoma radioresistance. We employed gain and loss of function approaches to validate the critical importance of these miRNAs as determinants of glioblastoma radiation resistance. Co-expression of miR1, miR125a, miR150, and/or miR425 in glioblastoma promotes radioresistance through upregulation of the cell-cycle checkpoint response. Such effects were not seen when each miRNA mimic was expressed individually. Antagonizing with antagomiRs sensitizes glioblastoma cells to irradiation, suggesting their potential as targets for inhibiting therapeutic resistance. Analysis of glioblastoma datasets from The Cancer Genome Atlas (TCGA) revealed that these miRNAs are expressed in glioblastoma patient specimens and correlate with TGFb signaling. Supporting this hypothesis, the expression of miR1 and miR125a can be induced by TGFb and antagonized by a TGFb receptor inhibitor. Together, these results provide insight into the therapeutic application of TGFb inhibitors in radiotherapy. Through an unbiased, systematic screen designed to identify miR combinations that confer glioblastoma radiation resistance, we uncovered a novel miRNA combination. The effects of the four miRNAs in aggregate was distinct from that seen with each individual siRNAs. The study points to the importance of an integrated study of miRNA combinations relative to the characterization of each individual miRNAs.
Long Term Survival After High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation in Metastatic Breast Cancer.
Authors: Betty K. Hamilton, Brian J. Bolwell, Lisa Rybicki, Shawnda Tench, Matt Kalaycio, Steven Andresen, Robert M Dean, Ronald Sobecks, Brad Pohlman, Brian T. Hill, Rabi Hanna, Hien K. Duong, Edward A. Copelan
Journal: Blood (2012)
Phase II trial of cixutumumab in combination with temsirolimus in pediatric patients with recurrent or refractory sarcoma: A report from the Children’s Oncology Group.
Authors: Lars M. Wagner, Maryam Fouladi, Atif Ahmed, Mark D. Krailo, Brenda Weigel, Steven G. DuBois, Austin Doyle, Helen X. Chen, Susan Blaney
Journal: Journal of Clinical Oncology (2014)

10066 Background: The combined inhibition of insulin-growth factor type 1 receptor (IGF-1R) and the mammalian target of rapamycin (mTOR) has shown activity in preclinical models of pediatric sarcoma and in adult sarcoma patients. We evaluated the activity of the anti-IGF-1R antibody cixutumumab with the mTOR inhibitor temsirolimus in patients with relapsed Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, and other soft tissue sarcoma. Methods: Cixutumumab 6 mg/kg and temsirolimus 8 mg/m2 were administered intravenously once weekly in 4-week cycles to patients < 30 years of age with recurrent or refractory sarcoma. Temsirolimus was escalated to 10 mg/m2 for subsequent cycles in patients who did not experience unacceptable first-cycle toxicity. A two-stage enrollment design was used to identify a response rate of < 10% or > 35%, with expansion of a tumor-specific cohort only if 2 or more complete or partial responses were seen in the first 11 patients. Tumor tissue was analyzed by immunohistochemistry for potential biomarkers of response. Results: Forty-three evaluable patients (median age 17 years, range 1-27) received a median of 2 cycles (range, 1-7). No objective responses were observed; 7 (16%) patients were progression-free at 12 weeks. Dose-limiting toxicity occurred in 15 (16%) of 92 cycles. The most common toxicities were mucositis, electrolyte disturbances, and myelosuppression. The lack of objective responses precluded correlation with tissue biomarkers. Conclusions: Despite encouraging preclinical data, the combination of cixutumumab and temsirolimus did not result in objective responses in this Phase II trial of pediatric sarcoma patients with recurrent or refractory disease. Clinical trial information: NCT01614795.
An Integrated Approach Identifies Mediators of Local Recurrence in Head and Neck Squamous Carcinoma
Authors: Francesca Citron, Joshua Armenia, Giovanni Franchin, Jerry Polesel, Renato Talamini, Sara D'Andrea, Sandro Sulfaro, Carlo M. Croce, William Klement, David Otasek, Chiara Pastrello, Tomas Tokar, Igor Jurisica, Deborah French, Riccardo Bomben, Emanuela Vaccher, Diego Serraino, Barbara Belletti, Andrea Vecchione, Luigi Barzan, Gustavo Baldassarre
Journal: Clinical Cancer Research (2017)

Purpose: Head and neck squamous cell carcinomas (HNSCCs) cause more than 300,000 deaths worldwide each year. Locoregional and distant recurrences represent worse prognostic events and accepted surrogate markers of patients' overall survival. No valid biomarker and salvage therapy exist to identify and treat patients at high-risk of recurrence. We aimed to verify if selected miRNAs could be used as biomarkers of recurrence in HNSCC.Experimental Design: A NanoString array was used to identify miRNAs associated with locoregional recurrence in 44 patients with HNSCC. Bioinformatic approaches validated the signature and identified potential miRNA targets. Validation experiments were performed using an independent cohort of primary HNSCC samples and a panel of HNSCC cell lines. In vivo experiments validated the in vitro results.Results: Our data identified a four-miRNA signature that classified HNSCC patients at high- or low-risk of recurrence. These miRNAs collectively impinge on the epithelial-mesenchymal transition process. In silico and wet lab approaches showed that miR-9, expressed at high levels in recurrent HNSCC, targets SASH1 and KRT13, whereas miR-1, miR-133, and miR-150, expressed at low levels in recurrent HNSCC, collectively target SP1 and TGFβ pathways. A six-gene signature comprising these targets identified patients at high risk of recurrences, as well. Combined pharmacological inhibition of SP1 and TGFβ pathways induced HNSCC cell death and, when timely administered, prevented recurrence formation in a preclinical model of HNSCC recurrence.Conclusions: By integrating different experimental approaches and competences, we identified critical mediators of recurrence formation in HNSCC that may merit to be considered for future clinical development. Clin Cancer Res; 23(14); 3769-80. ©2017 AACR.
Long-term follow up for a phase I trial HER2/neu-targeted T cells in women with advanced breast cancer.
Authors: Lawrence G. Lum, Archana Thakur, Zaid S. Al-Kadhimi, Gerald A. Colvin, Francis J. Cummings, Robert Duffy Legare, Don S. Dizon, Nicola Kouttab, Abby Maizel, William Colaiace, Qin Liu, Ritesh Rathore
Journal: Journal of Clinical Oncology (2014)

3075 Background: Anti-CD3 x anti-Her2 bispecific antibody (Her2Bi) retargeting transforms activated T cells (ATC) into non-restricted MHC specific cytotoxic T cells. This study reports a phase I immunotherapy trial beginning in 2001 (NCT00027807) in 23 women with Her2 0-3+ metastatic breast cancer consisting of 8 infusions of HER2Bi armed ATC (aATC) in combination with interleukin 2 (IL-2) and granulocyte-macrophage-colony stimulating factor to evaluate safety, feasibility, time to progression, median overall survival (OS), T cell trafficking and immune responses. Methods: ATC were expanded in IL-2 after anti-CD3 stimulation of mononuclear cells obtained from leukapheresis. Groups of 3 patients (pts) received 5, 10, 20, or 40 x 10e9 aATC per infusion. Results: Total episodes of Grade III-IV side effects for 23pts in decreasing order were chills, headache, nausea/vomiting, back pain, hypertension, and death of 1 pt from congestive heart failure due to digoxin toxicity. aATC persisted in the blood for a week or more and trafficked to tumors. Twelve out of 22 (54.5%) had stable disease (SD) or better. OS was 36.2 months (m) for all pts, 57.4 m for Her2 3+ pts (n=7), and 27.4 m for Her2 0-2+ pts (n=16) with a median follow-up of 36.2 m. For pts with SD, the OS was 57.9 m in the HER2 3+ pts (n=4) and 40 m in the HER2 0-2+ pts (n=7). For pts with progressive disease (PD), OS was 36.6 m in the Her2 3+ pts (n=3) and 21.3 m in the Her2 0-2+ pts (n=9). There was 1 partial response. aATC infusions induced anti-tumor cytotoxicity that persisted >4 m, Th1 cytokines, and increases in IL-12 after 2 weeks. Phenotyping, imaging of In labeled aATC, and tumor biopsies show that aATC circulate > 96 hrs, localize and persist in tumors. Conclusions: aATC infusions are safe with manageable side effects. The OS of 36.2 m is encouraging in heavily pretreated pts. Targeting HER2 positive and negative tumors with aATC induced anti-tumor responses, increased Th1 cytokines, and IL-12 serum levels. The clinical responses suggest that aATC infusions may provide a survival benefit in pts with both stable and progressive disease. These results provide the rationale for conducting phase II trials. Clinical trial information: NCT00027807.
Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy: PRO-BMI study
Authors: E.S. Lutrino, M. Tucci, O. Caffo, M. Di Maio, G. Procopio, C. Scagliotti, F. Mssari, A. Milano, F. Atzori, S. Barni, A. Gambino, C. Fontanella, C. Scavelli, S. Cinieri
Journal: Annals of Oncology (2016)
Targeted Inhibition of mTORC1 and mTORC2 by the Active-Site mTOR Inhibitors, PP-242 and OSI-027, Has Cytotoxic Effects In T-Cell Acute Lymphoblastic Leukemia
Authors: Camilla Evangelisti, Francesca Chiarini, Francesca Ricci, Pierluigi Tazzari, Andrea Pession, James A McCubrey, Alberto M. Martelli
Journal: Blood (2010)